TFBS Bioscience Inc.
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
TFBS Bioscience Inc. (6939) - Total Assets
Latest total assets as of June 2025: NT$1.52 Billion TWD
Based on the latest financial reports, TFBS Bioscience Inc. (6939) holds total assets worth NT$1.52 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TFBS Bioscience Inc. - Total Assets Trend (2020–2024)
This chart illustrates how TFBS Bioscience Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TFBS Bioscience Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TFBS Bioscience Inc.'s total assets of NT$1.52 Billion consist of 51.8% current assets and 48.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 34.4% |
| Accounts Receivable | NT$49.31 Million | 3.3% |
| Inventory | NT$12.88 Million | 0.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$22.35 Million | 1.5% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how TFBS Bioscience Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TFBS Bioscience Inc.'s current assets represent 51.8% of total assets in 2024, an increase from 36.3% in 2020.
- Cash Position: Cash and equivalents constituted 34.4% of total assets in 2024, up from 26.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 3.3% of total assets.
TFBS Bioscience Inc. Competitors by Total Assets
Key competitors of TFBS Bioscience Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
TFBS Bioscience Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TFBS Bioscience Inc. generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TFBS Bioscience Inc. is currently not profitable relative to its asset base.
TFBS Bioscience Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 9.89 | 10.72 |
| Quick Ratio | 2.40 | 9.77 | 10.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$377.90 Million | NT$ 783.46 Million | NT$ 1.01 Billion |
TFBS Bioscience Inc. - Advanced Valuation Insights
This section examines the relationship between TFBS Bioscience Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.55 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | NT$1.50 Billion |
| Market Capitalization | $5.38K USD |
Valuation Analysis
Below Book Valuation: The market values TFBS Bioscience Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: TFBS Bioscience Inc.'s assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for TFBS Bioscience Inc. (2020–2024)
The table below shows the annual total assets of TFBS Bioscience Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.50 Billion | +3.44% |
| 2023-12-31 | NT$1.45 Billion | +6.21% |
| 2022-12-31 | NT$1.36 Billion | +177.51% |
| 2021-12-31 | NT$491.30 Million | +70.38% |
| 2020-12-31 | NT$288.36 Million | -- |